Skip to main content

Oscar Health, Inc. 2026 Second Quarter Earnings Conference Call

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, will release its second quarter 2026 financial results before the market opens on Thursday, August 6, 2026.

Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows:

Live Call: (855) 761-5600
Conference ID: 7768132
Webcast

The call will be archived and available on Oscar’s investor relations website (ir.hioscar.com) following August 6, 2026 for a period of 90 days.

About Oscar Health
Oscar Health, Inc. is a leading healthcare technology company built on a full-stack platform and a relentless focus on member experience. Oscar Health helps make high-quality and affordable care more accessible for millions of people through Oscar’s Individual & Family plans and ICHRA solutions, Lucie Health Marketplace, and Trove Group. Consumers benefit from better choice, deeper engagement, and connection to high-value clinical care.

Contacts

Investor Contact:
Chris Potochar
VP of Investor Relations
ir@hioscar.com

Media Contact:
Dalya Browne
Senior Director, External Communications
press@hioscar.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  251.19
+5.23 (2.13%)
AAPL  337.00
+4.59 (1.38%)
AMD  545.09
+32.59 (6.36%)
BAC  58.18
+0.28 (0.48%)
GOOG  343.68
+4.32 (1.27%)
META  682.31
+9.00 (1.34%)
MSFT  497.75
+7.45 (1.52%)
NVDA  219.34
+5.44 (2.54%)
ORCL  150.59
+7.43 (5.19%)
TSLA  366.20
+8.12 (2.27%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.